文献速递血栓与止血

获得性血友病A的治疗:一项27年荷兰队列研究揭示的平衡之道

Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study.
PubMed 文献 · Am J Hematol · 2020-10-10

这项荷兰全国多中心回顾性队列研究(1992-2018年)纳入143例获得性血友病A患者,评估临床表现与治疗疗效及安全性。一线免疫抑制治疗以单用糖皮质激素为主(67.6%),单药治疗成功率35.2%,低于糖皮质激素联合环磷酰胺的80.0%和联合利妥昔单抗的66.7%(P < .05)。高抗FVIII抗体滴度、严重出血和单用糖皮质激素与较低完全缓解率相关,而联合治疗虽提高疗效但感染发生率显著高于单药(38.7% vs 10.6%;P = .001)。

要点

  • 一线单用糖皮质激素成功率35.2%,联合环磷酰胺80.0%,联合利妥昔单抗66.7%,P < .05。
  • 感染是联合治疗最重要的不良事件:联合治疗38.7% vs 单药10.6%,P = .001。
  • 总死亡率38.2%,感染致死占19.2%,致命性出血致死占7.7%。

核心结论

  • 获得性血友病A具有显著的疾病相关和治疗相关发病率与死亡率。
  • 高抗FVIII抗体滴度、严重出血和单用糖皮质激素与较低完全缓解率相关。
  • 糖皮质激素联合治疗的疗效被更高的感染率所掩盖,感染是最重要的死亡原因。
  • 治疗有效性与安全性之间的平衡需要持续监测并获得性血友病A和进一步识别预后标志物。

研究设计与样本

  • 荷兰全国多中心回顾性队列研究,纳入1992年至2018年共143例获得性血友病A患者。
  • 患者中位年龄73岁,男性占52.4%,中位随访16.8个月(IQR 3.6-41.5个月)。
  • 采用多因素logistic回归和Cox回归分析患者特征与临床结局之间的独立关联。

主要发现

  • 一线免疫抑制治疗主要为单用糖皮质激素(67.6%)、糖皮质激素联合环磷酰胺(11.9%)和糖皮质激素联合利妥昔单抗(11.9%),成功率分别为35.2%、80.0%和66.7%,P < .05。
  • 最终75%的患者达到完全缓解。
  • 高抗FVIII抗体滴度、严重出血和单用糖皮质激素与较低完全缓解率相关。
  • 感染是最重要的不良事件,联合治疗组感染发生率38.7% vs 单药组10.6%,P = .001。
  • 总死亡率38.2%,感染致死占19.2%,致命性出血致死占7.7%;高龄、潜在恶性肿瘤和ICU入住是死亡预测因素。

临床怎么用

  • 原文结论未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired hemophilia A (AHA) is a severe auto-immune bleeding disorder. Treatment of AHA is burdensome and optimal management is still unresolved. Therefore a retrospective nationwide multi-center cohort study (1992-2018) was performed to evaluate clinical presentation and treatment efficacy and safety of AHA in the Netherlands. Multivariate logistic and Cox regression analysis was used to study independent associations between patient characteristics and clinical outcomes. A total of 143 patients (median age 73 years; 52.4% male) were included with a median follow-up of 16.8 months (IQR 3.6-41.5 months). First-line immunosuppressive treatment was mostly steroid monotherapy (67.6%), steroids/cyclophosphamide (11.9%) and steroids/rituximab (11.9%), with success rates of 35.2%, 80.0% and 66.7% respectively, P < .05. Eventually 75% of patients achieved complete remission (CR). A high anti-FVIII antibody titer, severe bleeding and steroid monotherapy were associated with lower CR rates. Infections, the most important adverse event, occurred significantly more often with steroid combination therapy compared to steroids alone (38.7% vs 10.6%; P = .001). Overall mortality was 38.2%, mostly due to infections (19.2%) compared to 7.7% fatal bleeds. Advanced age, underlying malignancy and ICU admission were predictors for mortality. This study showed that AHA is characterized by significant disease-related and treatment-related morbidity and mortality. A high anti-FVIII titer, severe bleeding and steroid monotherapy were associated with a lower CR rate. The efficacy of steroid combination therapies however, was overshadowed by higher infection rates and infections represented the most important cause of death. The challenging and delicate balance between treatment effectivity and safety requires ongoing monitoring of AHA and further identification of prognostic markers.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Schep SJ, van Dijk WEM, Beckers EAM, et al. Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study. Am J Hematol. 2020. PMID: 32974947. doi:10.1002/ajh.26009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。